This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next

12/19/14 - 04:16 PM EST

U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.

READ FULL POST

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

12/19/14 - 08:25 AM EST

European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

READ FULL POST

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

12/16/14 - 11:20 AM EST

One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.

READ FULL POST

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

12/15/14 - 09:23 AM EST

Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.

READ FULL POST

Array Biopharma Regains Rights to Cancer Drug From Novartis

12/03/14 - 04:01 PM EST

The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.

READ FULL POST

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia

12/03/14 - 01:31 PM EST

Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.

READ FULL POST

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

12/02/14 - 04:34 PM EST

Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

READ FULL POST

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study

12/01/14 - 11:37 AM EST

All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.

READ FULL POST

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

11/24/14 - 09:39 AM EST

The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.

READ FULL POST

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

11/19/14 - 01:25 PM EST

The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 17,949.55 +144.75 0.81%
S&P 500 2,077.32 +6.67 0.32%
NASDAQ 4,779.3790 +13.9990 0.29%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs